We have agreed to reimburse the underwriters for certain expenses. Underwriting Discounts and Commissions (1) Any representation to the contrary is a criminal offense. Neither the Securities and Exchange Commission norĪny state securities commission has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. See Risk Factors beginning on page 11. Public company reporting requirements for this prospectus and future filings. We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced We intend to apply to list our common stock on The NASDAQ Global Market under the symbol KITE. We anticipate that the initial public offering price of ourĬommon stock will be between $ and $ per share. This is our initial public offering and no public market currently exists for our shares. SUBJECT TO COMPLETION, DATED MAY 19, 2014

Jurisdiction where the offer or sale is not permitted. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any These securities until the registration statement filed with the Securities and Exchange Commission is effective. The information in this preliminary prospectus is not complete and may be changed. Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with The Registrant hereby amends this registration Price of shares that the underwriters have the option to purchase. See theĭefinitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.Įstimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. Registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check theįollowing box and list the Securities Act registration statement number of the earlier effective registration statement for the same Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Under the Securities Act of 1933, check the following box. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 President, Chief Executive Officer, Chairman, FounderĪddress, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)Īpproximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices) (Exact Name of Registrant as Specified in Its Charter) As filed with the Securities and Exchange Commission on May 19, 2014

Kite pharma stocxk